Therapeutic management of ocular adnexal MALT lymphoma

Andrés J M Ferreri, Andrea Assanelli, Roberto Crocchiolo, Giuseppina P. Dognini, Antonio Giordano Resti, Letterio S. Politi, Claudio Doglioni, Federico Caligaris Cappio, Riccardo Dolcetti, Maurilio Ponzoni

Research output: Contribution to journalArticlepeer-review


Non-Hodgkin lymphomas constitute 50% of all orbital malignancies. Mucosa-associated lymphoid tissue (MALT)-type lymphoma is the most common histology category in this anatomic region. Ocular adnexal lymphoma of MALT-type is an indolent and rarely lethal malignancy that can often be managed with observation alone. Occasionally, lymphomatous lesions determine the symptoms that condition a patient's quality of life, and so require an immediate antineoplastic treatment. Several strategies are available, but reliable indications supported by prospective trials do not exist. Some therapeutic strategies are associated with substantial side effects and require a well-balanced therapeutic decision, which should take into account several variables related to the patient, the lymphoma, and the treatment itself. In this review, the authors analyze related literature and propose therapeutic guidelines for the management of ocular adnexal lymphoma of MALT-type.

Original languageEnglish
Pages (from-to)1073-1083
Number of pages11
JournalExpert Opinion on Pharmacotherapy
Issue number8
Publication statusPublished - Jun 2007


  • Chlamydia
  • Doxycycline
  • Extranodal lymphoma
  • Interferon
  • Mucosa-associated lymphoid tissue
  • Ocular adnexae
  • Rituximab

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Therapeutic management of ocular adnexal MALT lymphoma'. Together they form a unique fingerprint.

Cite this